Form 4: AN2 Therapeutics Director Receives Stock Grant
Insider Transaction (Form 4)
Gilbert Lynn Marks, a Director of AN2 Therapeutics, Inc., received 2,283 shares of common stock on October 12, 2026.
Summary
- Grant/award: acquired 2,283 Common Stock on October 12, 2026; holds 84,156 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Gilbert Lynn Marks — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-12 | Grant/award | Common Stock | 2,283 | — | — | 84,156 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-12 | Grant/award (2,283 shares) |
Keywords
insider transaction, Form 4, ANTX, AN2 Therapeutics, Inc., neutral, Gilbert Lynn Marks
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.